Fenofibrate Reversibly Increases Serum Creatinine Level in Chronic Kidney Disease Patients by Reducing Glomerular Filtration Rate

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Unknown venue

• Publication date

  2011-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Altered hepatic eicosanoid concentrations in rats treated with the peroxisome proliferators ciprofibrate and perfluorodecanoic acid

  2009cited by this paper
• Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people.

  2008cited by this paper
• Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1.

  2006influential reference
• PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice. Commentary

  2006influential reference
• Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

  2005cited by this paper
• Peroxisome proliferator-activated receptors and cardiovascular remodeling.

  2005cited by this paper
• Fenofibrate Increases Creatininemia by Increasing Metabolic Production of Creatinine

  2002cited by this paper
• Rhabdomyolysis and Acute Renal Failure after Changing Statin-Fibrate Combinations

  2001cited by this paper
• Deterioration in renal function associated with fibrate therapy.

  2001cited by this paper
• Effect of gemfibrozil on serum levels of prostacyclin and precursor fatty acids in hyperlipidemic patients with Type 2 diabetes.

  1998cited by this paper
• Induction of Cyclooxygenase-2 Expression by Peroxisome Proliferators and Non-tetradecanoylphorbol 12,13-Myristate-type Tumor Promoters in Immortalized Mouse Liver Cells*

  1997cited by this paper
• Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure.

  1996cited by this paper
• Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle Aged Men with Dyslipidemia

  1991cited by this paper
• Lipoproteins and apolipoproteins during the progression of chronic renal disease.

  1988cited by this paper
• Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

  1987cited by this paper
• Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives.

  1987cited by this paper

• Terminalia Sericea aqueous leaf extract protects growing wistar rats against fructose-induced fatty liver disease

  2018cites this paper
• Fibrates: Risk Benefits and Role in Treating Dyslipidemias

  2015cites this paper
• Effect of dietary Terminalia sericea aqueous leaf extracts on high-fructose diet fed growing Wistar rats

  2014influential citation